A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)

NCT03207347 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

37

Enrollment

OTHER

Sponsor class

Conditions

Mesothelioma
Uveal Melanoma
Renal Cell Carcinoma
Cholangiocarcinoma

Interventions

DRUG: Niraparib

Sponsor

University of Florida

Collaborators

[object Object]